Signs of Dapagliflozin Overdose in Adults in Intensive Care with Metformin Poisoning

What this Trial Is About

Researchers are studying patients admitted to intensive care units due to drug poisoning involving metformin, a medication commonly used for diabetes. The study compares two groups those who overdosed on metformin alone and those who overdosed on both metformin and dapagliflozin, another diabetes drug. The goal is to find clinical or biological signs that can help doctors quickly identify an overdose involving dapagliflozin in these patients, which may improve treatment decisions and patient outcomes. This observational study monitors patients admitted for metformin poisoning with or without dapagliflozin. No specific treatments are given as part of the study instead, researchers collect clinical and laboratory data from these patients over a period of up to 10 years. The study focuses on identifying differences in clinical presentation and biological markers between the two groups. Participants will be evaluated during their ICU stay with clinical assessments and laboratory tests as part of their usual care. Researchers will analyze these data to identify distinguishing features between the overdose types. The primary outcome measure is the identification of clinical and biological differences between patients who overdosed on metformin alone versus those with combined metformin and dapagliflozin overdose over a 10-year observation period. The study started in April 2025 and will continue until April 2026.

Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning